{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.81","upperLimit":"1.03","value":"0.92"},{"groupId":"OG001","lowerLimit":"0.76","upperLimit":"1.03","value":"0.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Overall survival is defined from study registration to death due to any cause or to the date of censoring measure at the last contact. KM method was used.","dispersionType":"95% Confidence Interval","groups":[{"description":"cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV","id":"OG000","title":"Experimental (Cis/Doce/Pembro)"},{"description":"Out of the experimental group these subjects had pathological complete response","id":"OG001","title":"PCR Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"first study registration to death due to any cause or date of censuring (up to 2 years follow up)","title":"To Determine the 2-year Relapse-free Survival (RFS) and Overall Survival (OS) in the Overall Population and in the Subgroup Who Achieves a pCR. (OS)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}